ArticleOncoimmunology2015
Immune signature of tumor infiltrating immune cells in renal cancer.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 114 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)
Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)
Who cites it
114 citing papers in PubMed, 181 citations in OpenAlex.
- Unconventional T cells in urological cancers: catch them if you can.Nature reviews. Urology · 2026Review
- Integrated multi-omics analysis reveals folate metabolism-related genes as prognostic markers and therapeutic targets in clear cell renal cell carcinoma.BMC cancer · 2026Article
- Review
- Comprehensive analysis of COLGALT1 in tumor microenvironment regulation and prognosis of clear cell renal cell carcinoma.Clinical and experimental medicine · 2026Article
- Article
- Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients.Oncoimmunology · 2025Article
- CXCR3 enhanced murine chimeric antigen receptor T cells in the treatment of solid tumors.Translational cancer research · 2025Article
- Article
- VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function.Cancer immunology, immunotherapy : CII · 2025Article
- Reduced somatosensory innervation alters the skeletal transcriptome at a single cell level in a mouse model of type 2 diabetes.Bone research · 2025Article
- Spatial expression of fibroblast activation protein-α in clear cell renal cell carcinomas revealed by multiplex immunoprofiling analysis of the tumor microenvironment.Cancer immunology, immunotherapy : CII · 2025Article
- Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer.Breast cancer research : BCR · 2024Article
- Multi-omics analysis of Prolyl 3-hydroxylase 1 as a prognostic biomarker for immune infiltration in ccRCC.NPJ precision oncology · 2024Article
- Comprehensive assessment of the association between tumor-infiltrating immune cells and the prognosis of renal cell carcinoma.World journal of clinical oncology · 2024Article
- DCS, a novel classifier system based on disulfidptosis reveals tumor microenvironment heterogeneity and guides frontline therapy for clear cell renal carcinoma.Journal of the National Cancer Center · 2024Article
- Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study.BMC cancer · 2024Article
- Single-cell transcriptomic analysis in clear cell renal cell carcinoma: Deciphering the role of APP within the tumour microenvironment.Journal of cellular and molecular medicine · 2024Article
- Assessment of Tumor-Associated Tissue Eosinophilia (TATE) and Tumor-Associated Macrophages (TAMs) in Canine Transitional Cell Carcinoma of the Urinary Bladder.Animals : an open access journal from MDPI · 2024Article
- Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma.MedComm · 2024Article
- Integrative bioinformatics andOncology research · 2024Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated immune cells have been discussed as an essential factor for the prediction of the outcome of tumor patients. Lymphocyte-specific genes are associated with a favorable prognosis in colorectal cancer but with poor survival in renal cell carcinoma (RCC). Flow cytometric analyses combined with immunohistochemistry were performed to study the phenotypic profiles of tumor infiltrating lymphocytes (TIL) and the frequency of T cells and macrophages in RCC lesions. Data were correlated with clinicopathological parameters and survival of patients. Comparing oncocytoma and clear cell (cc)RCC, T cell numbers as well as activation-associated T cell markers were higher in ccRCC, whereas the frequency of NK cells was higher in oncocytoma. An intratumoral increase of T cell numbers was found with higher tumor grades (G1:G2:G3/4 = 1:3:4). Tumor-associated macrophages slightly increased with dedifferentiation, although the macrophage-to-T cell ratio was highest in G1 tumor lesions. A high expression of CD57 was found in T cells of early tumor grades, whereas T cells in dedifferentiated RCC lesions expressed higher levels of CD69 and CTLA4. TIL composition did not differ between older (>70 y) and younger (<58 y) patients. Enhanced patients' survival was associated with a higher percentage of tumor infiltrating NK cells and Th1 markers, e.g. HLA-DR+ and CXCR3+ T cells, whereas a high number of T cells, especially with high CD69 expression correlated with a worse prognosis of patients. Our results suggest that immunomonitoring of RCC patients might represent a useful tool for the prediction of the outcome of RCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.